What is OnKure?
OnKure Therapeutics operates at the intersection of scientific discovery and clinical development, focusing on the identification of novel biological targets to treat cancer and other serious diseases. By leveraging a proprietary research platform, the company designs therapies that target specific underlying biological mechanisms, aiming to provide meaningful clinical benefits where traditional treatment options remain limited. As a key participant in the precision medicine landscape, OnKure maintains rigorous scientific evaluation and safety standards, positioning itself as a high-potential entity in the competitive biopharmaceutical market.
How much funding has OnKure raised?
OnKure has raised a total of $266M across 4 funding rounds:
Series A
$7M
Series B
$55M
Series C
$54M
Stock/Share Issuance
$150M
Series A (2018): $7M with participation from Delian Capital
Series B (2021): $55M led by Acorn Bioventures, BlackRock, Cormorant Asset Management, Samsara BioCapital, Perceptive Advisors, and Surveyor Capital
Series C (2023): $54M supported by Acorn Bioventures, Surveyor Capital, and Deep Track Capital
Stock/Share Issuance (2026): $150M, investors not publicly disclosed
Key Investors in OnKure
BlackRock
BlackRock is a global investment management firm providing comprehensive risk management and advisory services to institutional clients, managing a diverse portfolio across multiple asset classes.
Cormorant Asset Management
Cormorant Asset Management is a prominent life sciences investment firm that provides financial resources to support innovative companies in the biotech and allied sectors.
Perceptive Advisors
Perceptive Advisors is a specialized investment firm focused on funding innovative healthcare and life sciences technologies with a significant portfolio of assets under management.
What's next for OnKure?
With this major enterprise-level funding, OnKure is well-positioned to advance its clinical programs and expand its research capabilities. The strategic allocation of these funds will likely focus on accelerating the transition of its lead candidates through critical clinical trial phases, thereby enhancing the company's value proposition for future partnerships or potential market entry. As the firm matures, the focus will shift toward validating its therapeutic platform in larger patient cohorts, ensuring that its innovative approach to oncology translates into tangible, life-saving outcomes for patients globally.
See full OnKure company page
